{"id":"W1989760088","doi":"10.1007/s00384-007-0395-7","title":"Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNFα, improves health-related quality of life in patients with moderate to severe Crohn’s disease","year":2007,"lang":"en","type":"article","venue":"International Journal of Colorectal Disease","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Robarts Clinical Trials","funders":"","keywords":"Certolizumab pegol; Medicine; Placebo; Internal medicine; Crohn's disease; Quality of life (healthcare); Inflammatory bowel disease; Gastroenterology; Infliximab; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002614637,0.0002612426,0.0003796764,0.0002537606,0.00004732272,0.00004783738,0.0006449613,0.00008088985,0.00002653361],"category_scores_gemma":[0.0009482731,0.0002372764,0.0002357968,0.0001132101,0.000098005,0.00004448284,0.000181476,0.0001614685,0.000004894238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001844311,"about_ca_system_score_gemma":0.001301766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005032788,"about_ca_topic_score_gemma":0.0003682487,"domain_scores_codex":[0.9970508,0.0001691057,0.00128437,0.000321858,0.0008344282,0.000339405],"domain_scores_gemma":[0.9966024,0.000039548,0.0008965531,0.0003168172,0.001014535,0.0011302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3687624,0.002386089,0.6137649,0.000168372,0.0005858639,0.005359085,0.0003343206,0.00463999,0.001767266,0.0001461289,0.0007985004,0.001287054],"study_design_scores_gemma":[0.00603045,0.0006776848,0.9922258,0.0001292331,0.00003466113,0.00002236469,0.00004568274,0.0002141571,0.0001442632,0.0001431301,0.00006102305,0.0002715773],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970327,0.0002189345,0.00008935843,0.0009138045,0.000292635,0.0004835172,0.0008669008,0.000008787032,0.00009336972],"genre_scores_gemma":[0.9989482,0.000009586258,0.0002412434,0.0004038717,0.0001095811,0.00001010804,0.0001983,0.00003620424,0.00004286514],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3784608,"threshold_uncertainty_score":0.9675852,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008273711405574164,"score_gpt":0.2605176102723785,"score_spread":0.2522438988668043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}